DMAC
DiaMedica Therapeutics Inc.
Key Financials
Operating Income
$-34397000
↓ 28.9%
Net Income
$-32766000
↓ 34.0%
Total Assets
$61.4M
↑ 32.4%
Cash & Equivalents
$15.6M
↑ 417.3%
Shareholders' Equity
$56.1M
↑ 37.8%
Operating Cash Flow
$-29062000.00
↓ 31.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 8-K | 5/21/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DMAC |
| Company Name | DiaMedica Therapeutics Inc. |
| CIK | 1401040 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | Z4 |
| Phone | (763) 496-5454 |